Ojer Pharma and Bionaturis have signed a co-development, registration, and commercialization agreement to market Mupipet® in Europe, the first antibiotic with a bioadhesive and transparent formulation registered in Europe to treat skin bacterial infections in companion animals.

Mupipet® will be registered as a prescription veterinary drug for the topical treatment of skin bacterial infections in companion animals -such as pyoderma- being its main competitive advantage its cutting-edge formulation, developed and patented by the pharmaceutical company Ojer Pharma. Mupipet® is formulated in a transparent bioadhesive film, with acts as a controlled release matrix, ensuring the permanence of the active substance at the site of action and, as a result, a higher efficacy. This system makes unnecessary the use of dressing pads to cover the affected area and reduces product removal accidentally or by scratching and licking, which allows the treatment permanence for at least 12 hours. “The results of field studies already performed demonstrate that Mupipet® has better safety and efficacy profile that other reference products”, Carlos Gonzalez, General Manager at Ojer Pharma, has stated. “The isolation provided by this bioadhesive lipogel formulation reduces the risk of infections and protects the skin against external agents, as well as ensures the permanence of the product in the skin until the infection has been completely removed, with an excellent skin tolerability and non-irritant”, he has added.

“With this agreement, Mupipet® enriches our Premium portfolio for pets, in this case, under the category of prescription drugs. Due to its features, Mupipet® is a unique patent-protected product with outstanding competitive advantages versus other alternatives, and fitting our portfolio requirements. Besides, we expect this strategic agreement consolidates the relationship with Ojer Pharma to start the development of new innovative products. The transparent bioadhesive lipogel, owned by Ojer Pharma, opens up interesting new options for topical treatments in veterinary”, Bionaturis Group CEO, Victor Infante, has explained.

Meanwhile in the US there are some veterinary drugs for these indications already in the market, Mupipet® will be the first veterinary drug of this kind registered in Europe. The registration process to apply for the market authorization –MA- in Europe will start as soon as possible in order to reach distribution agreements right afterwards with third parties, already interested on Mupipetâ commercialization.

About Ojer Pharma

Laboratorios Ojer Pharma is a New Technology-Based Company –NEBTs- founded in 2015 by Carlos Gonzalez  with the support of Navarra University and other relevant Navarre institutions such as the Society for the Development of Navarre -SODENA, in Spanish)-. Ojer Pharma is devoted to the development of innovative pharmaceutical products and dermatological drugs to improve current standard treatments and to face dermatological diseases from a global perspective: treatment of causes and symptoms at once.

For further information about Ojer Pharma, please, visit its website

About Bionaturis Group

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis lists on the Spanish stock exchange for SMEs (trading code BNT).

Disclaimer

The Market and investors are informed that the Company’s developments are subject to significant risks and uncertainties, that include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Bionaturis’ ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Bionaturis’ patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 Currently, there are no guarantees that the development product will receive the necessary regulatory approvals or that they will prove to be commercially successful.